FOI_8527

Internal Reference Number: FOI_8527

Date Request Received: 21/03/2025 00:00:00

Date Request Replied To: 10/04/2025 00:00:00

This response was sent via: By Email

Request Summary: Ovarian Cancer

Request Category: Private Individuals


Question Number 1: How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

Answer To Question 1: 27 Patients

Question Number 2: How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib

Answer To Question 2: Paclitaxel in combination 7 patients, Platium based alone 0 patients, Bevacizumab 12 patients, Olaparib <5 patients, Olaparib plus bev <5 patients, Niraparib <5 patients, Rucaparaib <5 patients

Question Number 3: Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part

Answer To Question 3: The Trust were previously involved in two ovarian cancer studies: 1. Developing new tests for ovarian cancer (10 patients) and 2. mEOC study (with not more than 5 participants). Both studies are now closed, and there are currently no active ovarian cancer trials.

Question Number 4: If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with: Olaparib Olaparib + Bevacizumab Niraparib Other treatments

Answer To Question 4: <5 patients who are HRD positive started therapy in the last 3 months, as follows: <5 Chemotherapy +Bevacizumab <5 started maintenance therapy, <5 started Rucaparib, <5 started Olaparib +Bevacizumab all post 1st line chemotherapy.

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.